Treatment Strategies in Early NSCLC: The Role of Immunotherapy

Patrick Forde, MBBCh offers an overview of current standard-of-care treatments as well as emerging immunotherapy options for treating early-stage, resectable non-small cell lung cancer.

Patrick Forde, MBBCh, and Tina Cascone, MD, PhD, discuss the role of molecular profiling to guide precision treatment decisions in non-small cell lung cancer, including the impact of PD-L1 status on neoadjuvant and perioperative approaches.

Medical professionals discuss the role of neoadjuvant/perioperative immunotherapy in subgroups of patients with NSCLC with actionable genomic aberrations, including a brief look at the ALINA and ADUARA trials.

Panelists examine multidisciplinary teams and coordination of care for patients with non-small cell lung cancer, including when to involve surgeons, oncologists, and radiation oncologists.

Patrick Forde, MBBCh, and Tina Cascone, MD, PhD, discuss personalized treatment approaches for non-small cell lung cancer tailored to individual patient needs and goals.

Patrick Forde, MBBCh, discusses CheckMate-816 study results, including the high pathological complete response rates within 6 weeks of immunotherapy reported in the trial's third arm.

Tina Cascone, MD, PhD, analyzes results from the AEGEAN trial evaluating perioperative immunotherapy in stage II-IIIB non-small cell lung cancer.

Experts review the NEOTORCH study of 400 patients showing favorable outcomes with a hazard ratio for event-free survival of 0.4.

Medical professionals discuss perspectives on CheckMate-77T trial results and potential impacts on clinical practice.

Patrick Forde, MBBCh, and Tina Cascone, MD, PhD, discuss their institution’s approaches to treatment decision making for patients with resectable non-small cell lung cancer.

The panel discusses the future of ctDNA in clinical practice as well as sequencing decisions that may lead to adjuvant therapy in addition to neoadjuvant and/or perioperative therapy.

Patrick Forde, MBBCh, and Tina Cascone, MD, PhD, give final thoughts on unmet needs in the non-small cell lung cancer space to inform future treatment strategies.